Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29206809 | 0.77 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP2C19RAB9AL3MBTL1 | |
| SCHEMBL29770615 | 0.76 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP2C19RAB9AL3MBTL1 | |
| SCHEMBL20610132 | 0.76 | KDM4E (0.39) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL16387120 | 0.76 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP2C19RAB9AL3MBTL1 | |
| SCHEMBL19789223 | 0.76 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL15577470 | 0.76 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP2C19RAB9AL3MBTL1 | |
| SCHEMBL1853597 | 0.74 | TDP1 (0.52) | ALDH1A1CYP1A2CYP2C19L3MBTL1TDP1 | |
| SCHEMBL27238766 | 0.74 | ALDH1A1 (0.37) | ALDH1A1CYP1A2CYP2C19L3MBTL1TDP1 | |
| SCHEMBL611871 | 0.72 | ALDH1A1 (0.35) | ALDH1A1CYP1A2CYP2C19TDP1 | |
| SCHEMBL18725395 | 0.72 | ALDH1A1 (0.33) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4688772-A1 | BIARYL DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2026-01-15 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250206728-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | COILED THERAPEUTICS, INC. | 2025-06-26 | — | — | US | disclosed |
| CN-120040441-A | Compositions and methods for treating cancer | A2A制药有限公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025072722-A1 | METHODS FOR TREATING CANCERS ASSOCIATED WITH TRANSFORMING ACIDIC COILED-COIL PROTEINS | A2A PHARMACEUTICALS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119522217-A | Compositions and methods for treating cancer | A2A制药有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20090130209-A1 | Novel Pyridazinone Derivatives | AVENTIS PHARMA S.A. (FR) | 2009-05-21 | — | — | US | disclosed |
| US-7507734-B2 | Pyridazinone derivatives | AVENTIS PHARMA S.A. (FR) | 2009-03-24 | — | — | US | disclosed |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| EP-1753743-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1751141-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | Aventis Pharma S.A. (FR) | 2007-02-14 | — | — | EP | disclosed |
| EP-1604988-A1 | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005111018-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111019-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | AVENTIS PHARMA S.A. (FR) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598348-A1 | Novel pyridazinone derivatives as inhibitors of CDK2 | Aventis Pharma Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | POLB, POLA1, POLN | ALDH1A1 824/4885CYP1A2 558/4885CYP2C19 749/4885 |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | ALDH1A1 1052/4885CYP1A2 118/4885CYP2C19 115/4885 |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | GSK3B, GSK3A, PDXK | ALDH1A1 2673/4885CYP1A2 226/4885CYP2C19 217/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | ALDH1A1 840/4885CYP1A2 180/4885CYP2C19 419/4885 |
| US-20090130209-A1 | Novel Pyridazinone Derivatives | CDK2, CDK1, CDK20 | ALDH1A1 3043/4885CYP1A2 682/4885CYP2C19 760/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | ALDH1A1 589/4885CYP1A2 212/4885CYP2C19 914/4885 |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | CDK2, CDK1, CDK20 | ALDH1A1 3043/4885CYP1A2 682/4885CYP2C19 760/4885 |
| US-20250206728-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NTPCR, PTPRC, NFATC1 | ALDH1A1 1208/4885CYP1A2 4080/4885CYP2C19 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.